Search results for "hcv"
showing 10 items of 277 documents
Imūnā atbilde pret HCV vīrusa ARFP proteīnu un HCV genomu core/ARFP reģiona sekvenču analīze
2017
C hepatīta vīruss (HCV) ir viens no galveniem smagu aknu slimību izraisītājiem, HCV hroniskā infekcija bieži beidzas ar aknu cirrozi un hepatocelulāro karcinomu. Saskaņā ar Pasaules Veselības Organizācijas datiem aptuveni 71 miljons cilvēku cieš no hroniskas HCV infekcijas. Katru gadu no HCV izraisītām slimībām mirst aptuveni 399000 cilvēku. HCV ir apvalku saturošs vīruss ar vienpaviediena RNS genomu un pieder flavivīrusu (flaviviridae) dzimtai. Tas izplatās, galvenokārt, ar asins starpniecību. HCV vīrusam piemīt augsta ģenētiskā mainība, kas traucē pretvīrusa vakcīnas izstrādi. HCV genomā ir iekodēts poliproteīns, kas pec translācijas tiek procesēts par vīrusa strukturāliem un nestrukturāl…
Optimal therapy in hepatitis C virus genotypes 2 and 3 patients.
2011
Current guidelines recommend that patients with genotype 2 (G2) and 3 (G3) chronic hepatitis C be treated with pegylated interferon (PEG-IFN) plus low doses of ribavirin (800 mg/day) for 24 weeks, resulting in a sustained virological response (SVR) rate of approximately 80%. Considering these high response rates, several recent randomized trials have assessed whether shorter treatment (12-16 weeks) could be cost-effective in these patients. The results of these studies vary but suggest better responsiveness in G2 patients, and overall, do not strongly support reducing treatment to G3, viral load < 400 000 IU, low fibrosis, no metabolic cofactors), shorter treatment is as effective as standa…
Reducing treatment duration in patients infected with hepatitis C genotype 1: any need for further studies?
2009
The recommended treatment duration with pegylated interferon-α plus ribavirin for patients infected with hepatitis C virus (HCV) genotype 1 is 48 weeks. Interestingly, a subpopulation of genotype 1 patients experience rapid decreases in HCV RNA levels once treatment is initiated and attain rapid virological response, defined as undetectable HCV RNA at week 4 of therapy. Several studies have shown that these patients can be effectively treated for a 24-week period without any significant decreases in sustained virological response rates. The aim of this review was to consider the existing clinical evidence regarding the use of a 24-week treatment schedule among genotype 1 patients and to hi…
HCV Prevalence in Italy an Epidemiological, Observational, Cross-Sectional, Multicenter Study Participating Centers.
2012
There is a lack of updated nationwide records regarding hepatitis C virus (HCV) infection among drug addicts in Italy. The prevalence and characteristics of HCV infection in a national sample of drug addicts in Italy were determined. Five hundred forty-three drug addicts (mean age 35.3 years, 85.1% males), selected from 25 Italian Centers for Substance Dependence were enrolled to be evaluated for anti-HCV, HCV-RNA, HCV genotype, HBV markers, anti-HDV, and anti-HIV during the period of April-November 2009. Anti-HCV prevalence was 63.9%. HCV-RNA was detected in 68.3% of patients positive for anti-HCV. Genotypes 1 and 3 prevailed (49.3% and 39.7%, respectively). However, 9.3% of the subjects h…
Siero-prevalenza di marcatori di infezione da virus dell’epatite B, C ed HIV in una coorte di immigrati africani a Palermo, Sicilia.
2011
Obiettivi In Italia il 7% della popolazione è rappresentata da immigrati, dei quali oltre 127.000 sono legalmente residenti in Sicilia. Di questi, il 30,3% proviene da Paesi africani, prevalentemente dell’area sub-Sahariana, dove l’epidemiologia delle infezioni virali da virus dell’epatite B (HBV), dell’epatite C (HCV) e dell’immunodeficienza acquisita (HIV) è molto differente da quella europea. Il presente studio è stato condotto per valutare la sieroprevalenza di marcatori di infezione da HBV, HCV ed HIV in una coorte di individui immigrati dall’Africa sub-Sahariana e residenti in Sicilia. Metodi Un’analisi retrospettiva è stata condotta su un panel di 176 sieri, consecutivamente prelevat…